PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|February 23, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
- Volume 12
- Issue 3
PfizerCentreOne Expands Fill/Finish Services in Michigan
Author(s)Pharmaceutical Technology Editors
The company expanded fill/finish services at its facility in Kalamazoo, Michigan.
Advertisement
On Feb. 16, 2017, Pfizer CentreOne announced that it has expanded fill/finish services to its Kalamazoo, Michigan facility. Along with vial-filling of small molecules and biologics, the facility also provides vial-filling of sterile suspensions, expanding the company’s service portfolio. The Kalamazoo facility currently supplies drugs to more than 100 countries around the world.
Services at the Kalamazoo site now encompass small molecules and biologics, sterile suspensions, potent and controlled substances, aqueous and oil-based formulations, lyophilization, and vials 1–100mL; bulk formulation <1–1600 liters. The Kalamazoo facility also has dedicated, onsite technical, manufacturing science, regulatory affairs, and quality teams.
Source:
Articles in this issue
over 9 years ago
Viewpoint: No Clear Path for Pharma or Outsourcingover 9 years ago
Standards Set Excipient GMPs, But Collaboration is Neededover 9 years ago
Monitoring Supply Chain Risk on a Limited Budgetover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
Metrohm USA Announces Winner of Young Chemist Awardover 9 years ago
Novasep Opens New Bioconjugation Unit in Franceover 9 years ago
Recipharm Completes Kemwell AcquisitionAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement